Isabel Bover

11.1k total citations · 1 hit paper
48 papers, 2.1k citations indexed

About

Isabel Bover is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Reproductive Medicine. According to data from OpenAlex, Isabel Bover has authored 48 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 17 papers in Reproductive Medicine. Recurrent topics in Isabel Bover's work include Ovarian cancer diagnosis and treatment (17 papers), Lung Cancer Treatments and Mutations (17 papers) and Lung Cancer Research Studies (9 papers). Isabel Bover is often cited by papers focused on Ovarian cancer diagnosis and treatment (17 papers), Lung Cancer Treatments and Mutations (17 papers) and Lung Cancer Research Studies (9 papers). Isabel Bover collaborates with scholars based in Spain, France and United States. Isabel Bover's co-authors include Maciej Krzakowski, Kurt Krejcy, Joo Hang Kim, Yi‐Long Wu, Jayaprakash Madhavan, Stephen Begbie, Sung Hyun Yang, José Rodrigues Pereira, Valentina Tzekova and Eckart Laack and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Isabel Bover

45 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

2009 832 citations Tudor–Eliade Ciuleanu, Isabel Bover et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Isabel Bover Spain	13	1.3k	1.3k	401	247	228	48	2.1k
Andrew Dean Australia	17	694 0.5×	1.1k 0.9×	262 0.7×	267 1.1×	272 1.2×	104	1.6k
Vera Gorbounova Russia	13	1.8k 1.4×	2.2k 1.8×	617 1.5×	354 1.4×	282 1.2×	23	3.2k
Pavlos Papakostas Greece	26	841 0.6×	1.5k 1.2×	439 1.1×	315 1.3×	86 0.4×	104	2.2k
I. Brunetti Italy	21	623 0.5×	1.8k 1.4×	438 1.1×	212 0.9×	213 0.9×	65	2.4k
А. Н. Махсон Russia	15	563 0.4×	1.2k 1.0×	310 0.8×	397 1.6×	214 0.9×	23	1.7k
Mauro Orlando United States	22	926 0.7×	1.1k 0.8×	249 0.6×	177 0.7×	483 2.1×	88	1.9k
Karin Bowen United States	15	942 0.7×	1.3k 1.0×	809 2.0×	359 1.5×	334 1.5×	30	2.8k
James L. Freddo United States	13	568 0.4×	397 0.3×	563 1.4×	294 1.2×	150 0.7×	27	1.2k
Adam Pawinski Norway	21	558 0.4×	583 0.5×	414 1.0×	170 0.7×	104 0.5×	69	1.6k

Countries citing papers authored by Isabel Bover

Since Specialization

Citations

This map shows the geographic impact of Isabel Bover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabel Bover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabel Bover more than expected).

Fields of papers citing papers by Isabel Bover

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabel Bover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabel Bover. The network helps show where Isabel Bover may publish in the future.

Co-authorship network of co-authors of Isabel Bover

This figure shows the co-authorship network connecting the top 25 collaborators of Isabel Bover. A scholar is included among the top collaborators of Isabel Bover based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabel Bover. Isabel Bover is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

García-Donás, Jesús, Laia Garrigós, Núria Laínez, et al.. (2024). Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01). Clinical & Translational Oncology. 27(7). 3223–3231.

Fabbro, Michel, Kathleen N. Moore, Anne Dørum, et al.. (2019). Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology. 152(3). 560–567. 32 indexed citations

Romero, Ignacio, Ana Santaballa, Santiago González-Santiago, et al.. (2019). Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer. Anti-Cancer Drugs. 30(6). 628–635. 9 indexed citations

Fabbro, Michel, Kathleen N. Moore, Anne Dørum, et al.. (2017). Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC). Annals of Oncology. 28. v332–v332. 7 indexed citations

Gridelli, Cesare, Tudor–Eliade Ciuleanu, M. Dómine Gómez, et al.. (2017). Randomized double blind phase IIb trial in advanced NSCLC patients who did not progress after first line platinum based chemotherapy: Vx-001, a therapeutic cancer vaccine, vs placebo as maintenance therapy. Annals of Oncology. 28. v638–v638. 3 indexed citations

Isla, Dolores, Enriqueta Felip, Núria Viñolas, et al.. (2016). Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. Anticancer Research. 36(12). 6647–6654. 8 indexed citations

Oaknin, Ana, María Jesús Rubio, Andrés Redondo, et al.. (2015). SEOM guidelines for cervical cancer. Clinical & Translational Oncology. 17(12). 1036–1042. 26 indexed citations

Kurzeder, Christian, Isabel Bover, Frederik Marmé, et al.. (2015). Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.. Journal of Clinical Oncology. 33(15_suppl). 5504–5504. 5 indexed citations

González-Martı́n, Antonio, et al.. (2014). SEOM guideline in ovarian cancer 2014. Clinical & Translational Oncology. 16(12). 1067–1071. 9 indexed citations

10.

González-Martı́n, Antonio, Andrés Redondo, M. Jurado, et al.. (2013). GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clinical & Translational Oncology. 15(7). 509–525. 9 indexed citations

11.

Massutí, Bartomeu, Ramón Lecumberri, Albert Font, et al.. (2012). ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)—Final results.. Journal of Clinical Oncology. 30(15_suppl). 7095–7095. 4 indexed citations

12.

Cantos, Blanca, Margarita Majem, Pilar Garrido, et al.. (2012). Menstrual status and lung cancer in female patients from the Spanish WORLD07 database.. Journal of Clinical Oncology. 30(15_suppl). e12012–e12012. 3 indexed citations

13.

Bover, Isabel, Christian Rolfo, Eloísa Jantus‐Lewintre, et al.. (2011). Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop. Lung Cancer. 74(3). 535–543.

14.

Lianes, P., Jordi Remón, Isabel Bover, & Dolores Isla. (2011). SEOM guidelines for the treatment of malignant pleural mesothelioma. Clinical & Translational Oncology. 13(8). 569–573. 8 indexed citations

15.

Paz‐Ares, Luis, Helen J. Ross, Mary O’Brien, et al.. (2008). Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. British Journal of Cancer. 98(10). 1608–1613. 125 indexed citations

16.

Isla, Dolores, Enriqueta Felip, Pilar Garrido, et al.. (2007). P2-106: Gender differences in non-small cell lung cancer (NSCLC) patients (p): A retrospective study based in Spanish Lung Cancer Group(SLCG) trials.. Journal of Thoracic Oncology. 2(8). S533–S534. 1 indexed citations

17.

González-Martı́n, Antonio, Isabel Bover, María Jesús Rubio, et al.. (2005). Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study. Annals of Oncology. 16(5). 749–755. 90 indexed citations

18.

Muro, Xavier García del, Antonio López–Pousa, Javier Martín‐Broto, et al.. (2005). A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcoma. Cancer. 104(8). 1706–1712. 68 indexed citations

19.

Molina, Rafael, Xavier Filella, Rafael Fuentes, et al.. (2003). Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis. Tumor Biology. 24(4). 209–218. 232 indexed citations

20.

Muro, Xavier García del, Catalina Vadell, G. Pérez Manga, et al.. (1998). Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis. European Journal of Cancer. 34(1). 193–195. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact